Navigation Links
Avexa Reports Positive Phase IIb Result

hard work has paid off."

There were no Serious Adverse Events (SAEs) related to the study drug, and no patients withdrew from the study because of side effects of study drug treatment. ATC continues to be very well tolerated, with some patients having received more than 12 months treatment to date. Currently there are 14 patients in the open label section of the Phase IIb trial and 6 patients have elected to enter into an extension study (where they continue to be treated with ATC), having completed the full 48 weeks of the study.

"These outstanding results clearly position ATC to become the most effective and well tolerated NRTI for treatment of drug-resistant HIV," stated Dr Jonathan Coates, Avexa's CSO, and co-inventor of 3TC, a NRTI marketed by GSK.

The emergence of resistance to antiviral drugs is one of the most important reasons for treatment failure. No evidence of mutation in the virus resulting in resistance to ATC was detected over the course of the treatment. This indicates that antiviral resistance to ATC does not occur quickly and gives ATC a significant competitive advantage over several other drugs which can rapidly select for resistance.

"Overall the results of Avexa's Phase IIb clinical trial demonstrate that ATC is a clinically effective antiviral drug that can significantly reduce the replication of the virus in patients infected with drug-resistant HIV," said CEO Dr Julian Chick. "Moreover, these results demonstrate that ATC is a safe drug not associated with undesirable side effects. There was no evidence of ATC resistant virus emerging over the trial period. These results indicate that ATC has the properties required to position it as the NRTI of choice for the treatment of patients failing their first line or subsequent anti-HIV drug regimens."

Global HIV market

It is estimated that over 40 million people are currently infected with HIV, with over 1 million of these children. It is estimated that aro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avexas Apricitabine Clinical Trial Update
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Reports Positive Phase IIb Result
(Date:6/2/2015)... -- San MediTech, the industry leader in ... diabetics, announced its plan to attend the American Diabetes ... on June 5 th to 8 ... System (DGMS). The company plans to show industry experts ... and advancements made by Chinese medical device companies. San ...
(Date:6/2/2015)... today they are expanding their reach nationally by providing customers with on-site 17025 accredited pipette calibrations. ... ... ... ... Photo - http://photos.prnewswire.com/prnh/20150601/219758 ...
(Date:6/2/2015)... LOS ANGELES , June 2, 2015  CytRx ... development company specializing in oncology, today announced that it ... action pending in the Delaware ... of the Company,s current and former directors and officers, ... The lawsuit, captioned In re CytRx Corp. ...
Breaking Medicine Technology:San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 2San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 3San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 4Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 2Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 3Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 4CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
... MYL ) today commented on its response ... Mylan CEO Heather Bresch said, "We recognize the ... of patients with cancer, particularly the pediatric population, and ... to this important product. While Mylan has not had ...
... IRVINE, Calif., Feb. 14, 2012 Masimo (NASDAQ: ... its mission to "Improve Patient Outcomes and Reduce the Cost ... Applications®," and its confidence that continuous noninvasive hemoglobin monitoring (SpHb®) ... hospital-wide risk-share program for B lood T ransfusion ...
Cached Medicine Technology:Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 2Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 3Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 4Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 5Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 6Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 7
(Date:6/2/2015)... ANT Wireless, proven innovator in ultra-low ... (NPE) announcement of three next generation WASP bridge ... WASP-PoE-3. WASP is a standalone ANT (covering ANT, ... that allows data collected from low-power wireless sensors ... , The new generation of WASP ...
(Date:6/2/2015)... CRN International has been named a 2015 ... , a Connecticut state program that takes active steps to ... at appropriate companies. , Platform to Employment is being delivered ... Department of Labor. CRN, a 40-year-old radio marketing company near ... being recognized for its “hard work and dedication.” , CRN ...
(Date:6/2/2015)... Shimadzu Scientific Instruments today announces ... spectrometer. The newest model in the Ultra-Fast Mass ... ultrafast technologies (UF technologies) with new ion guide ... quality and higher throughput for a wide array ... features new technology, including a stronger vacuum system ...
(Date:6/2/2015)... 2015 DuPont Pioneer , one ... new seed warehouse and office facility in Zambia that ... for both local and export markets to Kenya, Tanzania ... emerge as the breadbasket for southern Africa provided an ... and South Central Africa senior business manager of DuPont ...
(Date:6/2/2015)... 2015 PhishLine, LLC today announced ... Swenson Drive, Suite 125 in Waukesha, Wisconsin 53186. ... new base of operations for PhishLine’s current corporate ... growth. , Mark Chapman, Founder and President, commented ... as enterprise customers adopt our market leading service ...
Breaking Medicine News(10 mins):Health News:ANT Technology Incorporated in Second Generation WASP Bridge Products 2Health News:ANT Technology Incorporated in Second Generation WASP Bridge Products 3Health News:CRN Named Company Partner of the Year by CT Employment Program 2Health News:Shimadzu’s New LC-MS/MS Provides Superior Speed and Sensitivity for the Utmost in Quantitative Detection and High-Speed Analysis 2Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 2Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2
... 19 California attorneys and a,presiding judge are among ... assemble next month in Los Angeles to discuss emerging ... Robert Berkes of Berkes Crane Robinson ... on asbestos litigation; Steven Kazan of Kazan McClain,Abrams Lyons ...
... (TSX: IM) ("IMRIS" or the "Company") today announced ... development and commercialization of MR-guided radiation therapy and ... (UHN) in Toronto. , The collaboration signals the ... guided radiation therapy, expanding on its existing expertise ...
... Feb. 19 The March of Dimes New York Division announced ... will return for a second year, to lead March for Babies(R) ... CBS 2 News Co-Anchor, Maurice DuBois , WCBS-TV/CBS 2 Sports ... morning program. "I,m very excited to be working with March of ...
... Region that affects addictive behavior is linked to ... (HealthDay News) -- The thrill-seeking behavior that makes ... might be based in an area of the ... , University of Kentucky and Purdue University researchers ...
... not possible, transplanting stem cells from the patient,s own bone marrow ... , The procedure has been tested successfully in ... been shown in 80% of cases, and considerable improvement in quality ... Hospital Clnic has used this therapy in a total of 6 ...
... Awards In January; Additional Cash Prizes Go to Support Best ... WarriorsWHITE PLAINS, N.Y., Feb. 19 Americans, renewed sense of ... the way to online solitaire. Thousands of ... games on behalf of their favorite charity or community organization. ...
Cached Medicine News:Health News:California Attorneys Featured at Major Asbestos Litigation Event 2Health News:IMRIS announces development program for MR guided radiation and interventional applications 2Health News:Eli Manning to Lead March for Babies(R) in Manhattan 2Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:New therapy with stem cells to treat Crohn's disease 2Health News:New therapy with stem cells to treat Crohn's disease 3Health News:New therapy with stem cells to treat Crohn's disease 4Health News:New therapy with stem cells to treat Crohn's disease 5Health News:Casual Gamers Join Forces With Top Charities to Compete for IWON.com Cash Prizes 2Health News:Casual Gamers Join Forces With Top Charities to Compete for IWON.com Cash Prizes 3
... midi gel dryer can dry 6 pieces of 10 ... area is 21 x 31 cm for laboratories to ... of silicon rubber with mask. Microprocessor controller controls temperature ... and the vacuum removes the moisture from below to ...
... To dry gels rapidly, evenly and safely, ... method. Heat and vacuum are applied beneath the ... Dries acrylamide and agarose gels up to 33 ... minutes., The heavy aluminum platen provides even heat ...
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... The Model 583 gel dryer is an ... acrylamide and agarose gels and dries these gels ... The dryer incorporates lid-mounted heater elements which heat ... x 45 cm. This 220-240 V unit includes ...
Medicine Products: